Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biatain Fiber Ag is a **soft, sterile, primary wound dressing** composed primarily of non-woven **carboxymethylcellulose (CMC) gelling fibers** reinforced with bicomponent fibers and contains **0.63% ionic silver (Ag+)** for antimicrobial efficacy, as well as **ethyl lauroyl arginate (LAE)**, a surfactant and chelator[5][1]. Upon absorption of wound exudate, the dressing forms a conformable gel, releasing silver ions within the dressing to kill microorganisms (antimicrobial action), aid in autolytic debridement, and maintain a moist environment conducive to healing[5][1]. It is specifically intended for *moderate to highly exuding acute and chronic wounds*, functioning as a barrier to bacterial penetration and minimizing infection risk[5][1]. The product features **low shrinkage, high tensile strength, and high absorption**, enabling easy removal and reducing the risk of exudate pooling and maceration. The dressing is typically used with a secondary dressing and is designed for both clinical and at-home use[5][1]. Developed and manufactured by Coloplast, Biatain Fiber Ag is undergoing clinical evaluation for approval in several markets, including Europe[6][7][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biatain Fiber Ag.